ASGR1 and liver cancer: Through specific binding with ASGPR, the nanodevice accurately recognizes liver cancer cells and releases DOX to achieve targeted treatment of liver cancer cells, reducing damage to normal cells, and enhancing the local concentration of the drug, thus improving therapeutic efficacy.